The Annual General Meeting (AGM) in Swedish Orphan Biovitrum AB (publ) took place on Thursday 26 April 2012 at 4.00 p.m. in Wallenbergsalen, at Kungliga Ingenjörsvetenskapsakademien (IVA), Grev Turegatan 16, Stockholm, Sweden.
CEO's presentation at the AGM
The slides from CEO Geoffrey McDonough's presentation at the AGM is avaliable for download under related documents.
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statement and the balance sheet and approved the proposal to carry forward the retained profits of SEK 4,583,105,488.
The board members and the chief executive officers were discharged from liability for the financial year 2011.
Election of Board of Directors, remuneration to the Directors and election of Auditor
The ordinary board members Adine Grate Axén, Bo Jesper Hansen, Lennart Johansson, Helena Saxon, Hans GCP Shikan and Hans Wigzell were re-elected and Matthew Gantz was elected as new board member. Bo Jesper Hansen was re-elected chairman of the Board.
Matthew Gantz was born 1965 and has a BA from Princeton University and an MBA from Harvard Business School. He is Regional US Executive Vice President and General Manager US in BTG, British Technology Group. Prior to BTG, he was Founder and CEO of Acureon Pharmaceuticals, President and CEO of Hydrabiosciences Inc, VP Europe for Chiron’s Biopharmaceutical Division and General Manager for PathoGenesis Europe. Prior to Chiron/PathoGenesis, Matthew held a variety of US sales and marketing roles at Abbott Laboratories Diagnostics Division. Matthew Gantz does not hold any shares or options in the company. He is independent in relation to the company and its management and in relation to the company’s principal shareholders.
The AGM approved the compensation to the Board in accordance with the nomination committee’s proposal.
PricewaterhouseCoopers AB was elected auditor of Sobi until the end of the annual general meeting 2013.
The AGM approved the proposed instructions and charter for the nomination committee.
Principles for remuneration for the management, long-term incentive program and transfer of own shares
The AGM approved the proposed guidelines for remuneration for the management.
The AGM also approved the Board’s proposal regarding the implementation of a long-term incentive program, and hedging arrangements in respect of the program including a directed issue of no more than 1,655,136 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 1,480,136 own common shares to program participants.
The Board’s proposal regarding transfer of no more than 88,551 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Share Program 2009, was also approved by the AGM.
For full details on each proposal adopted by the AGM please refer to the related documents list on this page.